NCT06156748Completed
CT Imaging for Guiding PA-TACE for HCC
CT Imaging for Guiding Postoperative Adjuvant Transarterial Chemoembolization for Hepatocellular Carcinoma
Source: ClinicalTrials.gov · Last updated 28 Jul 2025
Brief summary (registry, in English)
Postoperative adjuvant transarterial chemoembolization (PA-TACE) may improve survival outcomes in a subset of patients with resected hepatocellular carcinoma (HCC), reliable biomarkers for the criterion for the selection of candidates are lacking. The present study aimed to evaluate whether CT imaging can provide more value for predicting benefit from PA-TACE.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1770 (actual)
- First submitted
- 23 Nov 2023
- Start date
- 1 Oct 2019
- Primary completion date
- 30 Jun 2025
- Lead sponsor
- Zhujiang Hospital
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06156748
What you commit to
- Study type: Observational
- Participants enrolled: 1770
- From 1 Oct 2019 to the primary completion date, 30 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior antitumor treatment
Other illness
- Macrovascular thrombosis or metastasis
Other
- Perioperative mortality
- Unqualified image artifacts
- Tumor rupture
- MVI status not reported
Who the study is looking for
- CT scans acquired no more than one month before surgery
- Confirmation of HCC diagnosis by pathological examination
- Curative surgical resection
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhujiang Hospital of Southern Medical University Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.